X4 Pharmaceuticals, Inc
XFORNasdaq
$3.82
↓ -0.3%Jul 17 close · end-of-day
Price
1Y↑ +151.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$482.4M
Enterprise Value
$340.5M
P/E
—
P/S
59.6
P/B
2.9
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$8.1M
Net Income (TTM)
-$99.7M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-1206.7%
Net Margin
—
ROE
—
ROIC
-290.9%
Debt / Equity
0.4
Net Cash
$141.9M
Return 1Y
+156.4%
Company profile
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor. The company is also developing X4P-002, a CXCR4 antagonist for the. treatment of brain cancers.
- CEO
- Paula S. Ragan
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 80
- Headquarters
- Massachusetts
- Website
- x4pharma.com
Management & directors
- Kirske DavidChief Financial Officer
- Craig Adam RExecutive Chairman
- Volpone JohnPresident
Roles derived from SEC Form 4 filings.
Earnings
XFOR Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$2.5M↑ +177.8%
Diluted EPS-$0.16↓ -500.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $3.0M | $0.00 | $0.00 | $0.00 | $2.6M | $6.5M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$59.9M | -$85.1M | -$87.6M | -$107.5M | -$36.4M | -$86.9M |
| Net income | -$62.1M | -$88.7M | -$93.9M | -$101.2M | -$37.5M | -$79.2M |
| Diluted EPS | -$3.09 | -$3.99 | -$1.52 | -$17.07 | -$5.59 | -$1.87 |
| Operating cash flow | -$58.8M | -$70.9M | -$77.1M | -$96.5M | -$130.9M | -$85.6M |
| Free cash flow | — | — | -$77.2M | -$96.6M | -$131.2M | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -1995.8% | — | — | — | -1400.0% | -1336.7% |
| Net margin | -2071.0% | — | — | — | -1440.4% | -1218.4% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $563,000.00 | $560,000.00 | $1.5M | $900,000.00 | $1.7M | $1.6M | $2.3M | $2.5M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $71.1M | -$34.5M | -$35.7M | -$9.4M | -$26.2M | -$27.5M | -$23.7M | -$20.3M |
| Net income | $90.8M | -$36.7M | -$39.8M | $282,000.00 | -$25.7M | -$29.8M | -$23.9M | -$20.2M |
| Diluted EPS | $13.57 | -$5.48 | -$5.91 | $0.04 | -$3.47 | -$0.69 | $2.25 | -$0.16 |
| Operating cash flow | -$63.9M | -$34.0M | $628,000.00 | -$12.4M | -$29.9M | -$27.8M | -$15.5M | -$19.6M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | 12629.3% | -6160.7% | -2418.1% | -1049.2% | -1504.1% | -1756.6% | -1034.9% | -812.2% |
| Net margin | 16133.7% | -6552.9% | -2696.1% | 31.3% | -1476.0% | -1903.9% | -1044.8% | -809.6% |
Company news
May 27, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-30 | KIRSKE DAVID· Chief Financial Officer | Sale | 8,543 | $4.26 | $36,428.21 | filing |
| 2026-05-12 | KIRSKE DAVID· Chief Financial Officer | Sale | 16,961 | $4.29 | $72,820.36 | filing |
| 2025-10-23 | Craig Adam R· Executive Chairman | Buy | 86,206 | $2.90 | $249,997.40 | filing |
| 2025-08-14 | Volpone John· President | Award | 289,881 | $0.00 | $0.00 | filing |
| 2025-08-14 | Craig Adam R· Executive Chairman | Award | 289,881 | $0.00 | $0.00 | filing |
| 2025-08-14 | KIRSKE DAVID· Chief Financial Officer | Award | 193,254 | $0.00 | $0.00 | filing |
Latest 6 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.